India's GDP could rise by 1.5% if more older adults rejoin workforce: Report
Bengaluru:
Rohini Nilekani Philanthropies
has released a report titled 'Longevity: A New Way of Understanding Ageing', aimed at reframing how aging is understood and addressed in India.
This report is in collaboration with Dalberg Advisors and Ashoka Changemakers.
Drawing on insights from over a dozen expert organisations such as Carers Worldwide, WisdomCircle, Vayah Vikas, Silver Talkies, and others, the report explores aging through a comprehensive lens, focusing on four key dimensions based on the needs of older adults: economic security, health and well-being, social connectedness, and freedom to participate.
Backed by expert interviews and secondary data, the report highlights the overlooked economic and social contributions of India's older population.
According to the report, in 2023–24, older adults contributed approximately USD 68 million in labor income, or 3 per cent of India's GDP.
They also provided around 14 billion hours in unpaid family caregiving and 2.6 billion hours in community activities.
The report estimates a potential 1.5 per cent GDP boost if more older adults rejoin the workforce.
It calls for action in three key areas: raising public awareness of aging as a shared societal issue, supporting innovations to improve quality of life for older adults, and addressing systemic data and coordination gaps in the longevity ecosystem.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
2 days ago
- Business Standard
Lupin launches Prucalopride Tablets in US market
Lupinannounced the launch of Prucalopride Tablets, 1 mg, and 2 mg, in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., and indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity) had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025).
The Hindu
3 days ago
- The Hindu
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028
Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world's first malaria vaccine for children 'RTS,S' developed by GSK, PATH and partners, by more than half to less than USD 5 progressively by 2028. Announced as part of their commitment to the Vaccine Alliance (Gavi), the two companies said the price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. Lower vaccine cost through collaboration The announcement forms part of pledges to Gavi for its next replenishment phase -- Gavi 6.0, 2026-2030 -- by both companies, they said in a joint statement. "This pledge to Gavi 6.0 is more than a pricing announcement. It is a commitment to global equity, innovation, and collaboration. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families," Bharat Biotech International Ltd (BBIL) Executive Chairman Krishna Ella said. Further, he said, "By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria." GSK Chief Global Health Officer Thomas Breuer said the company had partnered with Bharat Biotech in 2021 with a common goal of finding a sustainable solution to get ahead of malaria. "Today, we announce GSK's contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO," he said. Breuer added, "This demonstrates our commitment to changing the trajectory of infectious diseases like malaria, making a difference in the lives of children and families across Africa." The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in the latest pledge to the Gavi replenishment, he noted. Boosting malaria immunisation drive With Gavi's support, 12 endemic countries in Africa will be introduced to RTS,S through routine immunisation programmes by the end of 2025. RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency and undertake the planned technology transfer to Bharat Biotech, the statement said. In parallel, Bharat Biotech has invested over USD 200 million in new, higher-output manufacturing facilities, product development and technology transfers. "These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete," it added. Gavi, the Vaccine Alliance CEO Sania Nishtar said, "Our ambition is to protect at least 50 million more children across Africa by the end of 2030, and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach."
Pink Villa
3 days ago
- Pink Villa
Meet Indian-born businessman who was forced to sell his Rs. 12,478 crore company for Rs 74
The story of a billionaire falling from their throne of power isn't new. The world of business sees rich men losing their glory in the blink of an eye all the time. However, the "rags to riches" story of the Indian-born businessman B.R. Shetty is rather a sad one. He once inspired entrepreneurs across the globe to chase their dreams and secured the spot of one of the wealthiest magnates in the world. But sadly, the man who once boasted an ultra-high net worth of over Rs. 20,000 Cr was left with nothing after making an unconsidered decision that caused irreversible damage to his name and assets. A Brief Look at B. R. Shetty's Power and Loss of Status Dr. Bavaguthu Raghuram Shetty was born in Udupi, Karnataka, India in 1942. He moved to the UAE when he was 31, reportedly with only a few dollars in his pocket. Shetty worked diligently to establish himself as the country's first medical representative. But he knew he did not want to settle for being a salesman. Several issues in the healthcare industry, including accessibility and cost, prompted the business mogul to embark on an entrepreneurial path, and he founded New Medical Centre Health in 1975. His journey was just getting started. Under his leadership, NMC became the first private healthcare provider in the country and successfully entered the global market. As the company became an integral part of the London Stock Exchange and the FTSE 100 Exchange, B. R. Shetty never had to look back. It wasn't long before he acquired the ownership of UAE Exchange and Travelex. He was well-acquainted with prominent figures like A.P.J. Abdul Kalam and even had plans to invest USD 5 billion for the betterment of the healthcare infrastructure in India. He is the proud owner of several successful business ventures, including Neopharma, BRS Ventures, and Finablr, according to reports. was once listed among Forbes' list of the richest men of India and lived in the lap of luxury. In 2019, his net worth reached USD 3 billion. He owned two floors in Burj Khalifa, and the Rolls-Royce collection was enough to evoke envy. So, where did it go wrong? Things started to go downhill when Muddy Waters Research, a USA-based investment firm, brought some serious allegations against him. Allegedly, Shetty's firm had a USD 1 billion debt, which he kept hidden from the investors. He soon had to give up his place on the NMC Health Board, and the company went under UK administration. Abu Dhabi Commercial Bank also filed a complaint against NMC and the Central Bank of UAE ordered a restraint on all his bank accounts and his firms were blacklisted, an investigation is ongoing against the business tycoon in India. B. R. Shetty is no longer a part of Forbes' billionaire list since 2020. Although he is nowhere near being poor, his current wealth doesn't hold a candle in front of his pre-2019 net worth. The accusations against him resulted in a price drop in shares, and he sold the business for Rs 74 to an Israel-UAE consortium. Shetty's rise and fall from grace almost imitate a tragic film. He was at the top once, but his fate played cruel tricks on him, and he lost everything almost overnight.
